Effect of L—NAME on nitric oxide and gastrointestinal motility alterations in cirrhotic rats

AIM: To invsstigare the effect of L-NAME on nitric oxide andgastriubtestubal motility alterations in cirrhotic ratsMETHODS: Rats with cirrhosis induced by carbontetrachloride were randomly divided into two groups, one( n= 13) receiving 0. 5 mg@ kg-1 per clay of NG-nitro-L-argininemethyl ester (L-NAME), a nitric oxide synthase inhibitor,for 10 days, whereas the other group ( n = 13) and control( n = 10) rats were administrated the same volume of 9 g@ L-1saline.Half gastric emptying time and 2 h residual rate weremeasured by SPECT, using 99m Tc-DTPA-labeled bariumsuifate as test meal. Gastrointestinal transition time wasrecorded simultaneously. Serum concentration of nitrcoxide (NO) was determined by the kinetic cadmiunreduction and colorimetric methods. ImmunohistochemicalSABC method was used to observe the expression anddistribution of three types of nitric oxide synthase (NOS)isoforms in the mt gastrointestinal tract. Western blot wasused to detect expression of gastrointestinal NOS isoforms.RESULTS: Half gastric emptying time and trans-gastrointestinal time were significantly prolonged( 124.0 ± 26.4min; 33.7± 8.9min;72.1 ± 15.3 min; P＜0.01), (12.4±0.5h; 9.5±0.3 h; 8.2±0.8 h; P＜0.01), 2h residual rate wasraised in cirrhotic rots than in controls and cirrhotic ratstreated with L-NAME(54.9± 7.6 % ,13.7 ± 3.2 %, 34.9± 10.3%, P＜ 0.01). Serum concentration of NO was significantlyincreased in cirrhotic rots than in the other groups (8.20 ± 2.48)μmol@L-1, (5.94± 1.07) μmol@L-1 ,and control (5.66± 1.60) tμmol@L-1, P＜ 0.01. NOS staining intensities which weremainly located in the gastrointestinal tissues were markedlylower in cirrhotic rats than in the controls and cirrhotic ratsafter treated with L- NAME.CONCLUSION: Gastrointestinal motility was remarkablyinhibited in cirrhotic rats, which could he alleviated by L-NAME. Nitric oxide may play an important role in theinhibition of gastrointestinal motility in cirrhotic rats.     

慢性间歇低氧对大鼠颏舌肌细胞线粒体功能的影响及脂联素的干预作用

目的 探讨慢性间歇低氧(CIH)对大鼠颏舌肌细胞线粒体功能的影响及脂联素干预作用.方法 健康雄性Wistar大鼠39只,采用随机数字表法分成健康对照(NC)组、CIH组、CIH脂联素干预组(CIH+Ad组),每组13只.NC组大鼠呼吸正常空气,CIH组与CIH+Ad组均接受CIH环境(CIH 8 h/d,共5周),CIH+Ad组加用经静脉脂联素注射10 μg/次,2次/周,共5周.于实验终止(第35天)时测定并比较各组大鼠血清脂联素浓度、颏舌肌线粒体膜电位、线粒体复合物Ⅰ活性、线粒体复合物Ⅳ活性.结果 CIH组血清脂联素浓度明显低于NC组[(1108±112)ng/ml,(2241±121)ng/ml,P＜0.01];CIH+Ad组高于CIH组[(1889±119)ng/ml]但低于NC组[(2241±121)ng/ml,均P＜0.01].CIH组颏舌肌线粒体膜电位相对值(1.82±0.11)明显低于NC组(2.09±0.14,P＜0.01),CIH+Ad组(1.98±0.09)较CIH组略高但低于NC组,差异均有统计学差异(均P＜0.05).CIH组线粒体复合物Ⅰ、Ⅳ浓度[(35.68±1.73)μmol·min-1·mg-1,(2.37±0.11)nmol·min-1·mg-1]最低,CIH+Ad组[(37.18±1.95)μmol·min-1·mg-1,(2.49±0.09)nmol·min-1·mg-1]及NC组[(39.02±1.38)μmol·min-1·mg-1,(2.81±0.12)nmol·min-1·mg-1]依次增高.NC组与CIH组比较差异有统计学意义(P＜0.01),CIH+Ad组与CIH组和NC组比较差异有统计学意义(均P＜0.05).结论 CIH可致大鼠血清脂联素水平降低,并能显著损伤颏舌肌细胞线粒体功能,补充外源性脂联素能部分改善CIH对大鼠颏舌肌细胞线粒体功能的损伤,提示低脂联素血症可能参与CIH导致的颏舌肌能量代谢障碍.

Abstract：

Objective To investigate the effect of chronic intermittent hypoxia (CIH) on mitochondrial function in genioglossus cells of rats and intervention role of adiponectin (Ad). Methods Thirty-nine healthy male Wistar rats were randomly divided into 3 groups, normal control (NC) group, CIH group and CIH + Ad group with 13 rats in each. Rats in NC group were kept breathing normal air, while rats in both CIH and CIH + Ad groups experienced the same CIH environment ( CIH 8 h/day for successive 5 weeks). However, rats in CIH + Ad group was given intravenous Ad supplement at the dosage of 10 μg,twice a week for sucessive 5 weeks. At the end of experiment ( day 35 ), the levels of plasma adiponectin,mitochondrial membrane potential activities of respiratory chain complexes Ⅰ and Ⅳ in mitochondrion of genioglossus cells were compared among different groups. Results Serum Ad level was significantly lower in CIH group than that in NC group [(1108 ± 112) ng/ml vs (2241 ± 121) ng/ml, P＜0.01 ]. Serum Ad level in CIH + Ad group [ ( 1889 ± 119) ng/ml] was significantly higher than that in NC group but lower than that in CIH group ( all P ＜ 0. 01 ). Mitochondrial membrane potential was significantly lower in CIH group than that in NC group [ ( 1.82 ± 0. 11 ) vs (2. 09 ± 0. 14), P ＜ 0. 01 ]. Mitochondrial membrane potential in CIH + Ad group ( 1.98 ± 0. 09) was higher than that in CIH group but lower than that in NC group ( all P ＜ 0. 05 ). The concentrations of mitochondrial respiratory chain complexes Ⅰ and Ⅳ in CIH group ( 35.68 ± 1.73 ) μmol · min - 1 · mg- 1 and (2. 37 ± 0. 11 ) nmol · min - 1 ·mg - 1, respectively) were the lowest but became higher from CIH + Ad group [ (37. 18 ± 1.95) μ mol· min-1 · mg-1 and (2. 49 ±0.09) nmol · min-1 ·mg-1 ,respectively] to NC group (39.02 ± 1.38) μmol · min-1 · mg-1 and (2. 81±0. 12) nmol · min-1 ·mg-1 ,respectively), with a significant difference between NC and CIH groups ( P ＜ 0. 01 ), between CIH + Ad and CIH groups ( P ＜ 0. 05 ), as well as between CIH + Ad and NC groups (P ＜ 0. 05 ). Conclusion CIH could lead to hypoadiponectinemia and impaired mitochondrial function in genioglossus cells of rats. Since such changes could be partially improved by supplement of adiponectin, it was suggested that hypoadiponectinemia might be involved in CIH-induced impairment of genioglossus energy metabolism.     

良性前列腺增生与肥胖相关性研究

目的 探讨良性前列腺增生(BPH)与肥胖或中心性肥胖的关系.方法 选择老年男性患者109例,分为BPH组(59例)和非BPH组(50例),检测血清前列腺特异性抗原(PSA)及性激素、血脂等相关生化指标;测量身高、体质量、腰围等物理指标;经腹超声测量前列腺体积,并随访至少3次.结果 肥胖组BPH患病率(73.33%)及超体质量组BPH患病率(64.28%)均较正常组(26.67%)增高(x2分别为13.991,6.836,均P＜0.002),中心性肥胖组BPH患病率(71.19%)较非中心性肥胖组(36.00%)明显增高(x2=12.156,P＜0.001);BPH组腰围身高指数、腰围、体质量、体质指数、臀围[0.56±0.05、(93.6±8.8)cm、(72.6±9.7)kg、(25.7±3.4)kg/m2和(100.2±6.6)cm]明显高于非前列腺增生组[0.52±0.06、(87.0±10.1)cm、(64.5±9.3)kg、(23.1±2.9)kg/m2和(95.6±8.1)cm](t分别=-3.30,-3.65,-4.38,-4.17,-3.18,均P＜0.01);肥胖组前列腺总体积高于正常组[(40.8±23.5)ml与(20.1±6.1)ml,t=-2.82,P＜0.01),中心性肥胖组明显高于非中心性肥胖组[(42.8±25.6)ml与(26.9±11.2)ml],(t=-3.93,P＜0.001);中心性肥胖组雌二醇/总睾酮(E2/TT)比值、胰岛素抵抗指数(HOMA-IR)(9.06±4.36、2.81±2.80)高于非中心性肥胖组(7.38±3.11、1.55±0.76)(t分别=-2.02,-4.24,均P＜0.05),血清TT、性激素结合蛋白(SHBG)则低于非中心性肥胖组[(4.54±1.54)nmol/L对(5.20±1.54)nmol/L,(45.8±17.24)nmol/L对(59.6±26.09)nmol/L,均t分别=2.16,2.79,P＜0.05];Logistic逐步回归分析表明,腰围是影响前列腺体积的主要因素(x2=19.52,P=0.000);前列腺总体积的年增长率在肥胖组同样高于正常组[(7.14±8.09)ml与(1.49±5.14)ml,t=-2.19,P＜0.05],在中心性肥胖组明显高于非中心性肥胖组[(7.96±13.81)ml与(1.35±5.36)m1,t=-3.28,P＜0.01];中心性肥胖组的前列腺特异性抗原密度(PSAD)低于非中心性肥胖组(0.048±0.036对0.090±0.093,t=2.02,P＜0.05);肥胖组的PSAD低于正常组(0.052±0.039与0.091±0.080,t=3.13,P＜0.01).结论 BPH的发生与肥胖,尤其是中心性肥胖密切相关,其机制可能与肥胖患者体内性激素失衡、生长激素-胰岛素样生长因子轴的紊乱有关.

Abstract：

Objective To explore the relationship between benign prostatic hyperplasia (BPH)and obesity. Methods The 109 elder men were divided into two groups: BPH group (n=59) and non-BPH group (n= 50). The blood samples were collected for the detections of prostate specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), insulin,androgen, estrogen, sex hormone binding globulin (SHBG) and dehydroepiandrosterone(DHEA).The anthropometric indexes including height, body weigh, waist circumference (WC), hip circumference (HC), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), waist-to-height ratio (WHtR) and waist-to-hip ratio (WHR) were measured and calculated. The total prostate volume (TPV) were measured by transabdominal ultrasonography three times at least. Results The morbidity rate of BPH was significantly higher in obesity group and over weight group than in health control group (73.33% and 64.28% vs. 26. 67%, x2 = 13. 991 and 6. 836, both P＜0. 002). So was in central obesity group versus in health control group (71.19% vs.36.00%, x2 =12. 156, P＜0. 001). The waist-height index, waist circumference, body weight, BMI and hip circumference were significantly higher in BPH group than in non-BPH group [(0. 56±0. 05)vs. (0.52±0.06), (93. 6±8.8) cm vs. (87.0± 10. 1) cm; (72.6±9.7) kg vs. (64.5±9.3) kg;(25.7±3.4) kg/m2 vs. (23.1±2.9) kg/m2; (100.2±6.6) cm vs. (95.6±8. 1) cm; t=-3.3, -3. 65, -4.38, -4. 17 and -3.18, respectively, all P＜0.01]. The TPV was higher in obesity groupthan in normal group [ (40.8± 23.5 ) ml vs. (20. 1 ± 6.1 ) ml, t = - 2.82, P＜ 0. 002] and obviously higher in central obesity group than in non-central obesity group [(42.8±25.6)ml vs. (26. 9±11.2)ml, t= -3. 93, P＜0. 001]. The ratio of E2/TT and HOMA-IR were higher in central obesity group [(9. 06±4.36) and (2.81 ±2. 80)] than in non-central obesity group [(7. 38±3. 11) and (1. 55±0.76), t= -2.02 and -4.24, both P＜0. 05]. Inversely, the TT and SHBG were lower in central obesity group than in non-central obesity group [(4.54 ± 1.54) nmol/L vs. (5.20 ± 1.54) nmol/L,(45.8± 17.24) nmol/L vs. (59.6 ± 26.09) nmol/L, t = 2.16 and 2.79, both P＜ 0. 05]. Logistic regression analysis showed that waist circumference was a major factor affecting TPV (x2= 19.52, P=0. 000). The annual growth rate of TPV was significantly higher in obesity group and central obesity group than in health control group [(7. 14±8. 09)ml vs. (1. 49±5.14)ml, (7. 96±13.81)mlvs. (1. 35±5.36)ml, t=-2.19 and -3.28, both P＜0. 05]; The PSAD was significantly lower in central obesity group than in health control group [(0. 048±0. 036) vs. (0. 090±0. 093), t=2.02, P＜0. 05], and lower in obesity group than in health control group [(0. 052 ±0. 039) vs. (0. 091 ±0. 080), t= 3. 13, P＜0. 01]. Conclusions The occurrence of BPH is closely related to obesity,especially central obesity. Its mechanism may be related to sex hormone imbalance and the GH/IGF-1 axis disorders in obese patients.     

营养性肥胖大鼠下丘脑增食欲素A基因的表达及其意义

目的 探讨营养性肥胖大鼠下丘脑组织中增食欲素A(Orexin A)的表达及其与高瘦素、高胰岛素和高脂血症的关系.方法 高脂膳食诱导建立营养性肥胖Wistar大鼠模型;采用放射免疫法和生化酶法检测肥胖大鼠血清瘦素、血清胰岛素及C肽、三酰甘油和总胆固醇;应用实时定量PCR分析法检测肥胖大鼠下丘脑组织中增食欲素A的表达.结果 喂养8周时,肥胖组大鼠体质量、Lee's指数、血糖、三酰甘油及总胆固醇水平较对照组均明显增加(P＜0.01);肥胖组大鼠血清瘦素(1.74±0.36)/μg/L、胰岛素(35±5)MIU/L和C肽含量(0.21±0.04)μg/L,均高于对照组(1.27±0.11)μg/L、(23±4)MIU/L和(0.14±0.03)μg/L,差异均有统计学意义(P＜0.01);肥胖组大鼠下丘脑组织中增食欲素A mRNA水平较对照组降低,分别为6.8±2.3和14.5±3.6(t=-8.06,P＜0.01);增食欲素A mRNA水平与血清瘦素(r=-0.726)、胰岛素(r=-0.506)及C肽含量(r=-0.664)显著负相关(均P＜0.01).结论 高脂饮食可诱导Wistar大鼠体内瘦素抵抗和营养性肥胖的发生,营养性肥胖大鼠下丘脑神经元增食欲素A基因的异常表达与瘦素水平及胰岛素抵抗的发生密切相关.

Abstract：

Objective To evaluate the relationships of the expression of orexin A in hypothalamus with hyperleptinemia, hyperinsulinism, and hyperlipidemia in alimentary obesity rats.Methods The alimentary obesity rat model was induced by high-fat diet in Wistar rats. The levels of leptin, insulin, C-peptide, total cholesterol (TC) and triglyeride (TG) were detected by luminescent immunoassay and biochemistry enzymic method. The gene expression of orexin A in rat hypothalamus was detected by real-time PCR. The correlation between orexin A and leptin was analyzed. Results After 8 weeks of high-fat diet feeding, the body weight, Lee's index, blood glucose, TG and TC significantly increased in obesity rat group (P＜0. 01). The levels of serum leptin, insulin and C-peptide were significantly higher in obesity rats than in controls [( 1.74±0. 36)μg/Lvs. (1.27±0.11) μg/L, (35±5) MIU/L vs. (23±4) MIU/L, (0.21±0.04) μg/L vs.(0. 14±0. 03) μg/L respectively, P＜0.01]. However, the level of orexin A mRNA was lower in obesity rats than in controls (6.8±2.3 vs. 14.5±3.6, t=-8.06, P＜0.01). The correlation coefficient (r) of orexin A mRNA with serum leptin, insulin, and C-peptide in alimentary obesity rat were -0. 726 (P＜0.01), -0. 506 (P＜0.01) and -0. 664 (P＜0.01), respectively. Conclusions High-fat diet can induce leptin-resistance and alimentary obesity in Wistar rat. The down-regulation of orexin A in rat hypothalamus would be correlated closely to the leptin and insulin resistance in alimentary obesity.     

Expression of growth hormone receptor and its mRNA in hepatic cirrhosis

AIM: To investigate the expression of growth hormone receptor (GHR) and mRNA of GHR in cirrhotic livers of rats with the intension to find the basis for application of recombinant human growth hormone (rhGH) to patients with liver cirrhosis.METHODS: Hepatic cirrhosis was induced in SpragueDawley rats by administration of thioacetamide intraperitoneally for 9-12 weeks. Collagenase Ⅳ was perfused in situ for isolation of hepatocytes. The expression of GHR and its mRNA in cirrhotic livers was studied with radio-ligand binding assay, RT-PCR and digital image analysis.RESULTS: One class of specific growth hormone-binding site, GHR, was detected in hepatocytes and hepatic tissue of cirrhotic livers. The binding capacity of GHR (RT, fmol/mg protein) in rat cirrhotic liver tissue (30.8±1.9) was significantly lower than that in normal control (74.9±3.9) at the time point of the ninth week after initiation of induction of cirrhosis (n=10, P＜0.05), and it decreased gradually along with the accumulation of collagen in the process of formation and development of liver cirrhosis (P＜0.05). The number of binding sites (×10 4/cell) of GHR on rat cirrhotic hepatocytes (0.86±0.16) was significantly lower than that (1.28±0.24)in control (n= 10, P＜0.05). The binding affinity of GHR among liver tissue, hepatocytes of various groups had no significant difference (P＞0.05). The expression of GHR mRNA (riOD,pixel) in rat cirrhotic hepatic tissues (23.3±3.1) was also significantly lower than that (29.3±3.4) in normal control (n=10, P＜0.05).CONCLUSION: The growth hormone receptor was expressed in a reduced level in liver tissue of cirrhotic rats,and lesser expression of growth hormone receptors was found in a later stage of cirrhosis. The reduced expression of growth hormone receptor was partly due to its decreased expression on cirrhotic hepatocytes and the reduced expression of its mRNA in cirrhotic liver tissue.     

瑞舒伐他汀干预野百合碱诱导大鼠肺动脉高压的实验研究

目的 探讨他汀类药物改善内皮细胞功能、抗增殖等降脂外作用在防治肺动脉高压中的作用及可能机制.方法 雄性SD大鼠,体重(255.7±12.5)g,皮下注射野百合碱诱导大鼠形成肺动脉高压,肺动脉高压形成前后分别接受瑞舒伐他汀预防和治疗.预防实验:32只SD大鼠随机分为4组,分别为瑞舒伐他汀低剂量(2 mg·kg-1·d-1)预防组(n=8)、瑞舒伐他汀高剂量(10 mg·kg-1·d-1)预防组(n=8)、肺动脉高压4周组(n=8)和正常对照4周组(n=8),野百合碱注射当日起预防组每日予瑞舒伐他汀灌胃至第4周末,正常对照组、肺动脉高压4周组仅予生理盐水灌胃.治疗实验:52只SD大鼠随机分为4组,分别为瑞舒伐他汀低剂量(2 mg·kg-1·d-1)治疗组(n=12)、瑞舒伐他汀高剂量(10 mg·kg-1·d-1)治疗组(n=12)、肺动脉高压8周组(n=20)和正常对照8周组(n=8),野百合碱注射4周后治疗组每日予瑞舒伐他汀灌胃至第8周末,正常对照组、肺动脉高压8周组仅予生理盐水灌胃.比较各组生存率、平均肺动脉压(mPAP)、肺小动脉管壁厚度、右心室肥厚程度,比较肺小动脉增殖细胞核抗原(PCNA)、内皮型一氧化氮合酶(eNOS)蛋白表达水平,比较肺组织Rho激酶1(ROCK-1)、eNOS mRNA表达水平.结果 预防实验大鼠均存活,肺动脉高压形成之后瑞舒伐他汀治疗能改善生存率(瑞舒伐他汀低剂量治疗组、瑞舒伐他汀高剂量治疗组与肺动脉高压8周组比较为58%、75%比30%,P均＜0.05);肺动脉高压形成之前和之后瑞舒伐他汀预防和治疗均能降低mPAP[预防实验:瑞舒伐他汀低剂量预防组、瑞舒伐他汀高剂量预防组与肺动脉高压4周组比较为(27.53±3.43)mm Hg(1 mm Hg=0.133 kPa)、(25.72±1.76)mm Hg比(36.05±2.45)mm Hg,P均＜0.01;治疗实验:瑞舒伐他汀低剂量治疗组、瑞舒伐他汀高剂量治疗组与肺动脉高压8周组比较为(30.39±3.17)mm Hg、(27.59±1.99)mmHg比(40.68±1.39)mm Hg,P均＜0.01],减轻肺小动脉管壁增厚、右心室肥厚程度(P均＜0.01),下调肺小动脉平滑肌细胞PCNA表达(P均＜0.01),上调内皮细胞eNOS表达(P均＜0.05),抑制ROCK-1基因表达(P均＜0.05),有一定的剂量依赖性(P均＜0.05).结论 瑞舒伐他汀防治肺动脉高压可能是通过抑制ROCK-1基因表达,抑制肺动脉平滑肌增殖和恢复内皮细胞功能等机制来实现的.

Abstract：

Objective To investigate the effects of rosuvastatin on monocrotaline (MCT)-induced pulmonary artery hypertension in rats. Methods Pulmonary arterial hypertension was induced by a single subcutaneous injection of monocrotaline (50 mg/kg) in rats. In the prevention protocol, 32 male SpragueDawley rats were randomly divided into four groups ( n = 8 each): low-dose rosuvastatin prevention group (2 mg · kg-1 · d-1 ), high-dose rosuvastatin prevention group ( 10 mg· kg-1 · d-1 ), pulmonary arterial hypertension group, normal control group. Beginning on the MCT injection day, rats were treated with rosuvastatin by daily gavage for 4 weeks. Normal control group and pulmonary arterial hypertension group received vehicle by garage. In the treatment protocol, 52 male Sprague-Dawley rats were randomly dividedinto four groups (n = 13 each): low-dose rosuvastatin treatment group (2 mg · kg-1 · d-1), high-dose rosuvastatin treatment group( 10 mg · kg-1 · d-1), pulmonary arterial hypertension group, normal control group. Four weeks after MCT injection, rats were treated with rnsuvastatin by daily gavage for 4 weeks.Normal control group and pulmonary arterial hypertension group received vehicle by gavage. At the end of study, survival rates, mean pulmonary arterial pressure (mPAP), wall thickness of small pulmonary artery and right ventricular hypertrophy among groups were compared. The expression levels of proliferating cell nuclear antigen (P CNA) and endothelial nitricoxide synthase (eNOS) protein in small pulmonary artery,the expression levels of Rho kinase 1 ( ROCK-1 ) and eNOS mRNA in lung tissue were also detected. Results All rats in the prevention protocol survived. Rosuvastatin treatment improved survival in the treatment protocol (58%, 75% vs. 30%, P ＜0. 05 ). Rosuvastatin therapy in both preventment or treatment protocols significantly lowered mPAP [prevention protocol: ( 27.53 ± 3.43 ), ( 25.72 ± 1.76 ) vs. ( 36. 05 ± 2. 45 )mm Hg(1 mm Hg =0. 133 kPa), P ＜0.01; treatment protocol: (30. 39 ±3. 17), (27.59 ±1.99) vs.(40. 68 ± 1.39) mm Hg, P ＜0. 01], reduced thickening of small pulmonary artery wall (P ＜0. 01 ) and right ventricular hypertrophy ( P ＜ 0. 01 ). Rosuvastatin also inhibited PCNA expression of SMC ( P ＜0. 01 ), restored eNOS expression of EC ( P ＜ 0. 05) and inhibited ROCK-1 mRNA expressions in lung tissue (P ＜ 0. 05 ). Conclusions Rosuvastatin therapy reduced mPAP in monocrotaline-induced pulmonary arterial hypertension rat model and this effect is linked with inhibition of ROCK-I expression, inhibition of smooth muscle cell proliferation and restoration of endothelial cell functions.     

先天抑郁大鼠内脏敏感性研究

目的 比较先天抑郁Fawn-Hooded(FH/Wjd)大鼠与Sprague-Dawley(SD)大鼠的内脏敏感性,探讨FH/Wjd大鼠作为精神障碍与肠易激综合征共病模型的可行性.方法 采用强迫游泳实验(FST)和糖水实验(SPT)验证FH/Wjd大鼠的抑郁特性.通过腹壁回撤反射(AWR)评估大鼠对不同压力结直肠扩张(CRD)的敏感性.免疫组织化学法检测大鼠结肠5-HT表达水平及结肠、大脑前额叶下边缘皮质(IL)、前边缘皮质(PrL)、前喙扣带回皮质(rACC)区域的c-fos表达水平.结果 FST中FH/Wjd大鼠水中静止时间显著长于SD大鼠(t＝8.931,P＝0.000).SPT中FH/Wjd大鼠糖水饮用量占总饮水量的比例显著低于SD大鼠(t＝4.155,P＝0.001).FH/Wjd大鼠在各CRD压力梯度(20、40、60、80 mm Hg,1 mm Hg=0.133 kPa)下的AWR评分均显著高于SD大鼠(t值分别＝-2.697、-3.464、-6.822、-3.976,P值分别＝0.022、0.006、0.000、0.003).FH/Wjd大鼠对照组结肠5-HT表达水平高于SD大鼠对照组(t=-11.371,P=0.000).FH/Wjd大鼠扩张组和SD大鼠扩张组结肠5-HT表达水平均较各自的对照组上升,且FH/Wjd大鼠表达水平高于SD大鼠(t＝-3.364,P＝0.007).FH/Wjd大鼠对照组和SD大鼠对照组结肠、前额叶各脑区c-fos表达水平差异无统计学意义(结肠:t＝-0.129、P＝0.900;IL:t＝-1.316、P＝0.218;PrL:t＝1.241、P＝0.243;rACC:t＝2.151、P＝0.057).FH/Wjd大鼠扩张组和SD大鼠扩张组结肠与前额叶脑区c-fos 表达水平均较各自的对照组显著上升,且FH/Wjd大鼠表达水平高于SD大鼠(结肠:t＝-5.864、P＝0.000;IL:t＝-2.530、P＝0.030;PrL:t＝-7.039,P＝0.000;rACC:t＝-6.489、P＝0.000).结论 先天抑郁FH/Wjd大鼠存在内脏高敏感性,其肠道高表达5-HT及结肠和大脑IL、PrL、rACC 区域对内脏伤害性刺激的高反应性.有可能作为精神障碍和肠易激综合征共病的动物模型.

Abstract：

Objective To explore the feasibility of inherent depressive Fawn-Hooded (FH/Wjd)rats as a comorbidity model of mental disorder and irritable bowel syndrome (IBS) by comparing visceral sensitivity of FH/Wjd rats and Sprague-Dawley (SD) rats. Methods Depression trait of FH/Wjd rats was validated through forced swimming test (FST) and sucrose preference test (SPT).Visceral sensitivity to colorectal distention (CRD) under various pressures was assessed by abdominal withdrawal reflex (AWR). The expression of 5-HT in rats' colon,c-fos expression in colon and brain areas of infralimbic cortex (IL),prelimbic cortex (PrL) and rostral anterior cingulated cortex (rACC)was tested with immunohistochemistry. Results FST indicated that the immobility time of FH/Wjd rats was significantly longer than that in SD rats (t=-8. 931,P＜0. 01). SPT showed that the ratio of sucrose water in total liquid consumed was significantly lower in FH/Wjd rats than that of SD rats(t=4. 155,P=0. 01). At each CRD pressure gradient (20,40,60 and 80 mm Hg,1 mm Hg=0. 133kPa),AWR score was all significantly higher in FH/Wjd rats than that of SD rats (t=-2. 697,-3.464,-6.822 and -3. 976,P=0. 022,0.006,0.000 and 0.003). The expression level of 5-HT in FH/Wjd rats' control group was significantly higher than that of SD rats' control group (t=-11.371,P=0. 000). Compared with their own control group,5-HT expression increased both in FH/Wjd rats dilated groups and SD rats dilated groups,and the expression level in FH/Wjd rats was higher than that of SD rats (t= -3. 364,P= 0. 007). There was no significant difference of c-fos expression in colon and prefrontal brain areas between FH/Wjd rats' control group and SD rats'control group (colon:t=-0. 129,P= 0. 900;IL:t=-1. 316,P= 0. 218;PrL:t=1. 241,P = 0. 243;rACC:t=2. 151,P = 0. 057). Compared with their own control group,the expression of c-fos in colon and prefrontal brain areas significantly increased both in FH/Wjd rats dilated groups and SD rats dilated groups,and the expression level in FH/Wjd rats was higher than that of SD rats (colon: t=- 5.864,P= 0.000;IL:t=-2. 530,P = 0. 030;PrL:t=-7. 039,P= 0. 000;rACC:t=-6. 489,P=0. 000). Conclusions Inherent depressive FH/Wjd rats present visceral hypersensitivity. Meanwhile,the expression of 5-HT in colon is high,and with hyperreactivity to visceral noxious stimuli in colon and brain IL,PrL,and rACC areas. FH/Wjd rats might be a comorbidity animal model of mental disorder and IBS.     

肝硬化大鼠内脏血红素氧合酶活性的变化

目的 在四氯化碳(CCl4)诱导大鼠肝硬化模型中,观察内脏血红素氧合酶(HO)活性的变化.方法 用CCl4制备大鼠肝硬化模型,采用动脉插管生理多导仪记录心率、平均动脉压的变化,门静脉插管测定门静脉压力,用联二亚硫酸盐还原法测定血浆一氧化碳(CO)水平,用胆红素生成量反映组织HO的活性.结果 与正常对照组相比,肝硬化组平...     

缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性的影响

目的 比较缬沙坦联合氨氯地平或氢氯噻嗪对老年高血压患者血压变异性及一氧化氮、内皮素的影响.方法选取61例2、3级老年高血压患者,随机分为两组,分别给予缬沙坦+氨氯地平或缬沙坦+氢氯噻嗪行降压治疗,观察入选时、治疗第8周和第16周各种相关指示的变化.人选时检测血脂、空腹血糖、血尿酸,试验各个阶段监测24 h动态血压,检测血浆一氧化氮、内皮素水平.结果在患者入选时、治疗第8周和第16周三个时间点,缬沙坦+氨氯地平组和缬沙坦+氢氯噻嗪组24 h血压及白昼血压比较差异无统计学意义.治疗第16周,缬沙坦+氨氯地平组晨峰收缩压较缬沙坦+氢氯嚷嗪组明显降低[(22.6±8.8)mm Hg(1 mm Hg=0.133 kPa)比(26.3±13.7)mm Hg,P＜0.05];缬沙坦+氨氯地平组及缬沙坦+氢氯噻嗪组24 h收缩压变异性(SBPV)进行性降低[缬沙坦+氨氯地平组:(12.5±2.8)mm Hg比(10.2 ±2.2)mm Hg比(8.8±1.6)mm Hg,P＜0.01;缬沙坦±氢氯噻嗪组:(12.5±2.5)mmHg比(10.7±2.2)mm Hg比(9.6±2.0)mmHg,P＜0.01],缬沙坦+氨氯地平组及缬沙坦+氢氯噻嗪组白昼SBPV明显降低[缬沙坦+氨氯地平组:(12.2±3.0)mm Hg比(10.1±2.3)mm Hg比(8.4±1.9)mm Hg,P＜0.01;缬沙坦+氢氯噻嗪组:(11.8±2.7)mm Hg比(10.4±1.9)mm Hg比(9.6±2.2)mm Hg,P＜0.01],缬沙坦+氨氯地平组24 h舒张压变异性(DBPV)显著降低[(15.5±3.4)mm Hg比(13.0±3.5)mm Hg比(12.3±2.5)mm Hg,P＜0.01],缬沙坦+氢氯噻嗪组24 h DBPV无显著性变化;缬沙坦+氨氯地平组第16周白昼SBPV低于缬沙坦+氢氯噻嗪组[(8.4±1.9)mm Hg比(9.6 ±2.2)mm Hg,p＜0.05],缬沙坦+氨氯地平第8周、第16周的24 h DBPV、白昼DBPV低于缬沙坦+氢氯噻嗪组(P ＜0.01～0.05);缬沙坦+氨氯地平组一氧化氮进行性升高[(27.3±13.6)μmol/L比(47.2±16.3)μmol/L比(69.5±18.9)μmol/L,P＜0.01]、内皮素进行性降低[(45.3±8.0)ng/L比(37.4±3.9)ng/L比(34.2±4.4)ng/L,P＜0.01];缬沙坦+氢氯噻嗪组一氧化氮进行性升高[(33.5±13.9)μmol/L 比(49.7±21.9)μmol/L比(66.7 ±24.7)μmol/L,P＜0.01]、内皮素显著降低[(46.6±10.4)ng/L比(37.0±5.4)ng/L比(36.1±8.2)ng/L,P＜0.01].治疗第8周,缬沙坦+氨氯地平组收缩压变异性的降幅与一氧化氮的升幅有相关性(r =0.401,P=0.025).结论缬沙坦联合氨氯地平或氢氯噻嗪均能降低老年高血压患者血压变异性、改善血管内皮功能,缬沙坦联合氨氯地平可能更适合于老年高血压患者.     

Effects of nitric oxide synthesis inhibitor in long-term treatment onhyperdynamic circulatory state in cirrhotic rats

AIM To investigate the effects of low dosage of nitric oxide synthesis (NOS) inhibitor NG-nitro-L-argininemethyl ester (L-NAME) in long-term treatment on hyperdynamic circulatory state in rats with cirrhosis.METHODS Cirrhosis model was induced in male SD rats by injection of 60% CC14 oily solutionsubcutaneously. Cirrhotic rats were treated with L-NAME (0.5 mg·kg-1·d-1) by gavage for two weeks. Meanarterial pressure (MAP), cardiac output (CO), cardiac index (CI), splanchnic vascular resistance (SVR),splanchnic blood flow (SBF) and serum NO levels were determinded in L-NAME-treated, L-NAME-untreated cirrhotic rats and controls by using 57Co-Labled microsphere technique and a fluorometric assay,respectively.RESULTS Untreated cirrhotic rats had significantly lower MAP, SVR and higher PP, CO, CI, SBF andNO concentration than controls ( 14.42±0,47 kPa vs 17.05±0.34 kPa, 2.974±0.186 kPa·mL-1·min-1 vs4.234±0.118 kPa·mL-1·min-1, 1.665±0.067 kPa vs 1.123±0.096 kPa, 189.99±9.26 mL/min vs 135.5±3.55 mL/min, 55.89±1.82 mL-1·min-1·100g-1 BW vs 39.68±1.64 mL-1·min-1·100g-1 BW, 4.60±1.25μmol/L vs 0.53±0.26 μmol/L, P<0.01, respectively). In treated cirrhotic rats, L-NAME significantlyattenuated the increase of CO, CI, SBF, NO concentration and the decrease of MAP and SVR. In treatedcirrhotic rats, L-NAME induced a marked decrement of NO concentration than untreated cirrhotic rats(1.471 ±0.907 μmol/L vs 4.204±1.253 μmol/L, P<0.01).CONCLUSION The endogenous NO may play an important role in the changes of hemodynamics pattern incirrhosis,and hyperdynamic circulatory state in rats with cirrhosis can be ameliorated by long-term low doseL-NAME treatment.     

丙氨酸转移酶升高的2型糖尿病患者伴有更多的心血管风险因素

根据血丙氨酸转氨酶(ALT)水平将4 509例2型糖尿病患者分为A组(n=449,ALT增高)和B组(n=4 060,ALT正常),ALT升高的患者为10%.与B组患者相比,A组患者相对年龄更轻[(48.5±11.3对55.7±11.4)岁,P＜0.01]、糖尿病病程更短[(36.8±45.0对56.2±58.8)个月,P＜0.01]、体重指数以及腰臀比更大[(27.7±3.9对25.8±3.4)kg/m2,P＜0.01;0.95±0.06对0.93±0.07,P＜0.01].两组之间的血压存在差别[收缩压(132±19对131±21)mm Hg,1 mm Hg=0.133 kPa,P=0.60;舒张压(78±10对75±10)mm Hg,P＜0.01].A组的空腹血糖[(9.04±2.91对8.63±3.05)mmol/L,P=0.008]、餐后血糖[(13.85±4.67对13.07±4.92)mmol/L,P=0.002]、HbA1C(8.11%±1.82%对7.74%±1.96%,P＜0.01)、空腹胰岛素[(10.59±7.31对7.97±7.18)mU/L,P＜0.01]和餐后胰岛素[(48.96±43.80对35.25±32.37)mU/L,P＜0.01]及稳态模型评估的胰岛素抵抗指数(HOMA-IR,4.11±2.85对3.00±2.92,P＜0.01)、甘油三酯[(2.77±2.50对2.19±2.99)mmoL/L,P＜0.01]明显增高,高密度脂蛋白胆固醇[HDL-C,(1.20±0.30对1.29±0.83)mmol/L,P=0.01]更低.Logistic回归分析说明,HbA1C、餐后胰岛素、HOMA-IR、尿酸和尿白蛋白与ALT水平正相关,HDL-C则为负相关.提示ALT增高的2型糖尿病患者发病年龄更轻,有更严重的胰岛素抵抗和更多的心血管危险因素.     

结核性胸膜炎中的IL-27对Th22细胞分化的影响

目的 探讨结核性胸腔积液IL-27对辅助性(Th) 22细胞定向分化过程的影响.方法 2014年6月至2015年6月在佛山市第一人民医院呼吸内科住院并且经胸腔镜取胸膜活检由病理学确诊的结核性胸膜炎患者20例,其中男11例,女9例,年龄25～60岁,平均35 5岁.从患者胸腔积液中的分离纯化出初始Th细胞,以含有抗-CD3+抗CD28单克隆抗体的基础培养条件为对照组,实验组则加入重组人IL-27、肿瘤坏死因子α(TNF-α) +IL-6或IL-27+ TNF-α+IL-6进行培养;在部分实验中,实验组为胸腔积液上清作为分化培养条件,加或不加入IL-27受体/Fc段嵌合体.培养7d后,使用流式细胞仪检测分化后的Th细胞表达IL-22以及特异性核转录因子芳香烃受体(AHR)的百分比.结果 对照组的Th22细胞比例为(2 2±0.9)％,AHR的比例为(4.2±0.8)％.与对照组相比,TNF-α+IL-6组的Th22细胞比例为(13.2±3.5)％、AHR的比例为(19.5±5.0)％,两者的比例显著上调(t=13.7、11.6,均P＜o.05).IL-27组的Th22细胞比例为(2.0±0.6)％、AHR的比例为(3.3±0.8)％,与对照组相比,两者的比例差异均无统计学意义(t =0.2、0.7,均P＞0.05).与TNF-α+ IL 6组相比,IL-27+TNF-α+IL 6组的Th22细胞比例为(6.0±2.0)％、AHR的比例为(8.4±2.6)％,两者的比例均显著下调(t =8.9、8.4,均P＜0.05);后续实验中,与对照组的Th22细胞比例(2.4±1 0)％以及AHR比例(4.2±1.1)％相比,胸腔积液上清组的Th22细胞比例(5.2±1.3)％以及AHR比例(6.5±1.6)％均显著上调(t=4.3、3.3,均P＜0.05).与胸腔积液上清组相比,胸腔积液上清+ IL-27受体/Fc段嵌合体组的Th22细胞比例(8.2±2.6)％以及AHR比例(13.8±2.0)％均进一步地显著上调(t=4.4、10.7,均P＜0.05).结论 IL-27本身不引起Th22细胞的分化,但对由TNF α+IL-6诱导的Th22细胞分化过程具有负向调节作用,在结核性胸膜炎微环境中能够抑制过强的Th22反应.     

缬沙坦对心力衰竭家兔钙调蛋白依赖性蛋白激酶Ⅱ的影响

目的 探讨家兔慢性心力衰竭(心衰)时心肌钙调蛋白依赖性蛋白激酶Ⅱ(CaMKⅡ)蛋白表达及活性的改变及血管紧张素Ⅱ受体拮抗剂缬沙坦长期干预的意义.方法 27只家兔随机分为3组,假手术组、心衰组和缬沙坦组各9只,通过超容量负荷联合压力负荷建立家兔心衰模型,于术后7周观察左心室结构、血液动力学的变化及CaMK Ⅱ的表达和活性的改变.结果 与假手术组比较,心衰组左室重量指数(LVMI)、左窒舒张末压显著升高(P＜0.05),左室短轴缩短率及左室射血分数明显降低(P＜0.05);与心衰组比较,缬沙坦组左室重量指数、左室舒张未压显著降低(P＜0.05),左室短轴缩短率及左室射血分数明显升高(P＜0.05);心衰组CaMK Ⅱ蛋白表达及活性显著高于假手术组(P＜0.05);缬沙坦组CaMKⅡ蛋白表达及活性显著低于心衰组(P＜0.05).结论 缬沙坦长期干预心衰,能够改善心脏舒缩功能,可能与其降低CaMK Ⅱ蛋白表达及活性有关.     

高敏C-反应蛋白及颈动脉粥样硬化与急性脑梗死的关系

目的 探讨和分析血清高敏C-反应蛋白(hs-CRP)及颈动脉粥样硬化与急性脑梗死的关系.方法 选取59例急性脑梗死患者为脑梗死组,同期选择健康体检者30例为对照组,测定血清hs-CRP含量,应用颈动脉彩色多普勒超声检查颈动脉粥样硬化斑块及颈动脉内膜-中膜厚度(IMT).同时对急性脑梗死患者血清hs-CRP水平与病情进行相关分析.结果 血清hs-CRP脑梗死组为(5.96±1.52)mg/L高于对照组的(1.78±1.02)mg/L(t=15.383,P＜0.01);颈动脉斑块检出率急性脑梗死组为77.97%,高于对照组的36.67%(x2=12.92,P＜0.01);颈动脉IMT脑梗死组(1.18±0.17)mm高于对照组的(1.02±0.15)mm(t=4.544,P＜0.05);神经功能缺损程度重型组血清hs-CRP水平[(15.68±1.45)mg/L]明显高于轻型组[(1.88±0.34)mg/L]和中型组[(4.16±1.39)mg/L](t值为37.217和25.243,P＜0.01).结论 血清hs-CRP水平升高对急性动脉粥样硬化性脑梗死病变有临床意义,早期测定hs-CRP水平有助于评估急性脑梗死患者的病情及预后.     

联合降压对中青年女性高血压病患者性功能的影响

目的 探讨以非洛地平为基础的联合降压方案在降压达标的基础上对中青年女性高血压病患者性功能的影响.方法 研究采用前瞻性、随机、平行、对照、开放、固定治疗的设计方案.选择2008-2009年在兰州大学第二医院就诊的中青年(年龄18～60岁)女性1～2级高血压病患者99例,随机分2组:非洛地平缓释片5 mg/d+厄贝沙坦片150 mg/d(F+I组,n=49),非洛地平缓释片5 mg/d+琥珀酸美托洛尔片47.5 mg/d(F+M组,n=50).以美国女性性功能指数量表(FSFI)进行问卷调查并检测血清雌二醇和总睾酮的含量,随访24周.FSFI总分以小于25.5定义为性功能障碍,以血压＜140/90 mm Hg(1 mm Hg=0.133 kPa)为达标.结果 F+I组与F+M组治疗第4、8、12周和第24周血压达标率分别为42.9%比62.0%、89.8%比90.0%、93.9%比94.0%和98.0%比96.0%,两组之间比较差异均无统计学意义(均P＞0.05).绝经前与绝经后患者在F+I组治疗后性欲指数和性唤起功能指数均升高(P分别＜0.05或＜0.01),雌二醇水平升高[绝经前:(50.3±37.4)pg/L比(54.4±10.8)pg/L,绝经后:(18.4±2.9)pg/L比(20.2±3.1)pg/L,P分别＜0.05或＜0.01],睾酮水平下降[绝经前:(722.8±277.1)ng/L比(650.0±156.0)ng/L,绝经后:(841.2±279.3)ng/L比(761.9±197.8)ng/L,P分别＜0.05或＜0.01];在F+M组治疗后性欲指数和阴道湿润度指数均降低(均P＜0.01),雌二醇水平降低[绝经前:(57.4±9.7)pg/L比(51.1±12.1)pg/L,绝经后:(19.8±2.3)pg/L比(17.8±3.3)pg/L,均P＜0.01],睾酮水平升高[绝经前:(775.6±217.8)ng/L比(886.0±186.4)ng/L,绝经后:(812.5±311.3)ng/L比(914.4±300.2)ng/L,均P＜0.01].高血压组FSFI总分与年龄和收缩压水平均呈负相关(均P＜0.01).结论 非洛地平缓释片与厄贝沙坦片或琥珀酸美托洛尔片联合降压达标率相同.前者可以在一定程度改善女性高血压病患者性功能.     

多发性肌炎/皮肌炎合并间质性肺疾病的相关因素及预后不良因素分析

目的 探讨多发性肌炎/皮肌炎(PM/DM)患者发生间质性肺疾病(ILD)的相关因素及影响预后的不良因素.方法 以上海第二军医大学长海医院1997年1月至2006年11月收住的PM/DM患者87例为研究对象,分为ILD组40例(男13例,女27例),平均年龄(54±13)岁;非ILD组47例(男25例,女22例),平均年龄(45±18)岁.对ILD的发生率、临床特征和预后进行分析.正态分布的计量资料采用t检验,偏态分布的计量资料采用秩和检验,计数资料两组率的比较采用x2检验,PM/DM伴发ILD的预测因素和预后不良因素采用logistic回归分析和Kaplan-Meier生存曲线.结果 PM/DM中ILD的发生率为46％(40/87),病死率为40％(16/40).ILD组的平均年龄[(54±13)岁]明显大于非ILD组[(45±18)岁];ILD组出现发热(21/40)、吞咽困难(16/40)、关节痛(26/40)、Gottron皮疹(14/40)和心脏损害(26/40)的百分率明显高于非ILD组(分别为7/47、8/47、9/47、2/47和14/47);ILD组的血清乳酸脱氢酶[(472±285)IU]和ESR[(44 ±24)mm/1 h]明显高于非ILD)组[(310±238)IU和(26±24)mm/1 h];ILD组的IgG[(18±9)g/L]明显高于非ILD组[(14±5)g/L].经多因素非条件logistic回归分析,筛选出4个与ILD相关的预测因子:Gottron皮疹、关节痛、发热和年龄≥40岁,其相对危险度分别为12.048、7.812、6.329和5.236;生存分析结果显示,Gottron皮疹、心脏损害和肺间质病变是影响ILD预后的不良因素.结论 PM/DM患者年龄≥40岁,出现Gottron皮疹、关节痛和发热与ILD的发生密切相关,Gottron皮疹、心脏损害和肺间质病变是影响ILD预后的不良因素.     

牙周基础治疗对老年牙周疾病患者血清炎性标记物的影响

目的 观察患有牙周病的老年人经过牙周基础治疗后,其冠心病相关血清炎性标记物的变化.方法 选择老年牙周病患者52例,记录其探诊深度(probing depth,PD)、附着水平(attachment level AL)、C-反应蛋白(C-reactive protein,CRP)和白细胞介素-6(interleukin-6 IL-6)水平.牙周基础治疗后3个月、6个月再次检查牙周临床指标,测定CRP和IL-6水平,比较治疗前后各项指标的变化.结果 治疗后6个月,PD和AL值分别为(5.9±1.1)mm和(6.8±1.0)mm,与治疗前[分别为(7.5±1.2)mm和(8.4±1.1)mm]比较,差异有统计学意义(均P＜0.05).CRP和IL-6分别为(1.5±0.2)mg/L和(1.6±0.5)ng/L,与治疗前[分别为(2.0±0.3)mg/L和(1.9±0.4)mg/L]比较,差异有统计学意义(分别为P＜0.01,P＜0.05).结论 牙周基础治疗能降低老年牙周疾病患者冠心病相关血清炎性标记物CRP和IL-6的水平.

Abstract：

Objective To ascertain serum inflammatory markers could be modified following treatment of periodontal disease in elderly patients. Methods The probing depth (PD), clinical attachment level (AL), C-reactive protein (CRP), interleukin-6 (IL-6) were determined. And then fifty-two elderly periodontitis patients underwent a standard phase of non-surgical periodontitis treatment (consisting of oral hygiene instructions and subgingival scaling and root planning). After three and six months, PD, AL, CRP and IL-6 were determined again and compared to the baseline. Results Six months after treatment, significant reductions in PD [(5.9±1.1) mm vs. (6.8±1.0) mm, P＜0.05], AL [(1.3±0.9) mm vs.(8.4±1.1) mm, P＜0.05], CRP [(1.5±0.2) mg/L vs. (2.0±0.3) mg/L, P＜0.01] and IL-6 [(1.6±0.5) ng/L vs. (1.9±0.4) ng/L, P＜0.05] were observed. Conclusions Treatment of chronic periodontitis can decrease the levels of serum inflammatory markers in elderly patients.